The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 101–200 of 1,004
Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease
Grover, S., Sreelatha, A. A. K., Pihlstrøm, L., Domenighetti, C., Schulte, C., Sugier, P., Radivojkov‐Blagojevic, M., Lichtner, P., Mohamed, O., Portugal, B., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200699 · Cited by 84
Self-citationProbiotics: Protecting Our Health from the Gut
Varela-Trinidad, G. U., Domínguez-Díaz, C., Solórzano-Castanedo, K., Íñiguez-Gutiérrez, L., Hernández-Flores, T. D. J., & Fafutis‐Morris, M. (2022) · Microorganisms · doi:10.3390/microorganisms10071428 · Cited by 80
Clinical applications of EEG power spectra aperiodic component analysis: A mini-review
Pani, S. M., Saba, L., & Fraschini, M. (2022) · Clinical Neurophysiology · doi:10.1016/j.clinph.2022.08.010 · Cited by 80
Pan, H., Liu, Z., Ma, J., Li, Y., Zhao, Y., Zhou, X., Xiang, Y., Wang, Y., Zhou, X. C., He, R., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00456-6 · Cited by 76
Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions
Sakowski, S. A., Koubek, E. J., Chen, K. S., Goutman, S. A., & Feldman, E. L. (2024) · Annals of Neurology · doi:10.1002/ana.26897 · Cited by 83
Contribution of proteases to the hallmarks of aging and to age-related neurodegeneration
Rai, M., Curley, M., Coleman, Z., & Demontis, F. (2022) · Aging Cell · doi:10.1111/acel.13603 · Cited by 72
Amin, R., Quispe, C., Docea, A. O., Ydyrys, A., Kulbayeva, M., Durna Daştan, S., Calina, D., & Sharifi-Rad, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105376 · Cited by 74
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders
Malar, D. S., Thitilertdecha, P., Ruckvongacheep, K. S., Brimson, S., Tencomnao, T., & Brimson, J. M. (2023) · CNS Drugs · doi:10.1007/s40263-023-01007-6 · Cited by 77
He, S., Wang, Q., Chen, L., He, Y. J., Wang, X., & Qu, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04638-x · Cited by 72
Chu, C., Yu, L., Li, Y. H., Guo, H., Zhai, Q., Chen, W., & Tian, F. (2023) · Nutrients · doi:10.3390/nu15071737 · Cited by 71
Wodrich, A. P. K., Scott, A. W., Shukla, A. K., Harris, B. T., & Giniger, E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.831116 · Cited by 73
Applications of nanobodies in brain diseases
Zheng, F., Pang, Y., Li, L., Pang, Y., Zhang, J., Wang, X., & Raes, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978513 · Cited by 69
Tönges, L., Buhmann, C., Klebe, S., Klucken, J., Kwon, E. H., Müller, T. H., Pedrosa, D. J., Schröter, N., Riederer, P. F., & Lingor, P. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02498-1 · Cited by 72
Chen, Z., Ho, M. M., & Chau, P. H. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12933 · Cited by 70
Durán, R. C., González-Orozco, J. C., Velasco, I., & Wu, J. Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.884748 · Cited by 64
The Promise of Niacin in Neurology
Wuerch, E. C., Urgoiti, G. B. R., & Yong, V. W. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01376-2 · Cited by 75
Álvarez, M. M., Cano-Herrera, G., Martínez, M. F. O., Gonzales-Portillo, J. V., Monroy, G. R., Pérez, R. M., Torres-Ríos, J. A., van Tienhoven, X. A., Bernot, E. M. G., Salazar, F. E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137183 · Cited by 77
Liu, Z., Yang, N., Dong, J., Tian, W., Chang, L., Ma, J., Guo, J., Tan, J., Dong, A., He, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31168-9 · Cited by 67
dos Santos, J. C. C., Oliveira, L. F., Noleto, F. M., Gusmão, C. T. P., Brito, G. A. D. C., & Viana, G. S. D. B. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373673 · Cited by 73
Nie, L., Yao, D., Chen, S., Wang, J., Pan, C., Wu, D., Liu, N., & Tang, Z. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01532-9 · Cited by 69
Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease
Takahashi, S., & Mashima, K. (2022) · Antioxidants · doi:10.3390/antiox11010170 · Cited by 73
CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Rahman, M. U., Bilal, M., Shah, J. A., Kaushik, A. K., Teissèdre, P., & Kujawska, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061252 · Cited by 65
Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease
Saha, P., Kathuria, H., & Pandey, M. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.021 · Cited by 67
Rusz, J., Krack, P., & Tripoliti, E. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105922 · Cited by 74
Zhang, H., Cao, X., Wang, L., Tong, Q., Sun, H., Gan, C., Shan, A., Yuan, Y., & Zhang, K. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14309 · Cited by 63
Clinical severity in Parkinson’s disease is determined by decline in cortical compensation
Johansson, M. E., Toni, I., Kessels, R. P. C., Bloem, B. R., & Helmich, R. C. G. (2023) · Brain · doi:10.1093/brain/awad325 · Cited by 69
Self-citationYue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62
Blood–brain barrier (BBB)-on-a-chip: a promising breakthrough in brain disease research
Peng, B., Hao, S., Tong, Z., Bai, H., Pan, S., Lim, K., Li, L., Voelcker, N. H., & Huang, W. (2022) · Lab on a Chip · doi:10.1039/d2lc00305h · Cited by 61
Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease
Imbriani, P., Martella, G., Bonsi, P., & Pisani, A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105851 · Cited by 63
Ferroptosis in Parkinson's disease —— The iron-related degenerative disease
Yao, Z., Jiao, Q., Du, X., Jia, F., Chen, X., Yan, C., & Jiang, H. F. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102477 · Cited by 65
Zhou, J., Hou, D., Zou, W., Wang, J., Luo, R., Wang, M., & Hong, Y. (2022) · Molecules · doi:10.3390/molecules27113645 · Cited by 61
Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease
Muñoz‐Delgado, L., Labrador‐Espinosa, M. Á., Macías‐García, D., Jesús, S., Zamora, B. B., Fernández‐Rodríguez, P., Adarmes-Gómez, A. D., Castillo, M. I. R., Castro‐Labrador, S., Silva‐Rodríguez, J., et al. (2023) · Movement Disorders · doi:10.1002/mds.29369 · Cited by 61
Mitochondrial complex I deficiency stratifies idiopathic Parkinson’s disease
Flønes, I. H., Toker, L., Sandnes, D. A., Castelli, M., Mostafavi, S., Lura, N. G., Shadad, O., Fernández‐Vizarra, E., Painous, C., Pérez‐Soriano, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47867-4 · Cited by 67
Advances in diagnosis, classification, and management of pain in Parkinson's disease
Tinazzi, M., Gandolfi, M., Artusi, C. A., Bannister, K., Rukavina, K., Brefel-Courbon, C., de Andrade, D. C., Perez-Lloret, S., & Mylius, V. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00033-x · Cited by 60
Sawicka-Gutaj, N., Zawalna, N., Gut, P., & Ruchała, M. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00377-w · Cited by 57
Wang, B., Wang, Y., Qiu, J., Gao, S., Yu, S., Sun, D., & Lou, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110827 · Cited by 64
Microglial response to aging and neuroinflammation in the development of neurodegenerative diseases
Han, T., Xu, Y., Sun, L., Hashimoto, M., & Wei, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385845 · Cited by 64
Kaagman, D. G. M., van Wegen, E. E. H., Cignetti, N., Rothermel, E., Vanbellingen, T., & Hirsch, M. A. (2024) · Brain Sciences · doi:10.3390/brainsci14030194 · Cited by 75
Dopaminergic system and neurons: Role in multiple neurological diseases
Chen, H., Li, J., Huang, Z., Fan, X., Wang, X., Chen, X., Guo, H., Liu, H., Li, S., Yu, S., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110133 · Cited by 69
Liu, S.-Y., Qiao, H.-W., Song, T.-B., Liu, X.-L., Yao, Y.-X., Zhao, C.-S., Barret, O., Xu, S.-L., Cai, Y.-N., Tamagnan, G. D., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02574-z · Cited by 62
Lifestyle Interventions for the Prevention of Parkinson Disease
Daalen, J. M. J., Schootemeijer, S., Richard, E., Darweesh, S. K. L., & Bloem, B. R. (2022) · Neurology · doi:10.1212/wnl.0000000000200787 · Cited by 63
Self-citationLiu, T., Zuo, H., Ma, D., Song, D., Zhao, Y., & Cheng, O. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02843-5 · Cited by 59
Pires, P. C., Paiva‐Santos, A. C., & Veiga, F. (2023) · Pharmaceuticals · doi:10.3390/ph16101424 · Cited by 61
Zhang, W., Ling, Y., Chen, Z., Ren, K., Chen, S., Huang, P., & Tan, Y. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01163-z · Cited by 59
Lian, B., Zhang, J., Yin, X. L., Wang, J., Li, L., Ju, Q., Wang, Y. J., Jiang, Y., Liu, X., Chen, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101684 · Cited by 64
Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
Lu, R., Zhang, L., & Yang, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1018848 · Cited by 58
Translational molecular imaging and drug development in Parkinson’s disease
Haider, A., Elghazawy, N. H., Dawoud, A., Gebhard, C., Wichmann, T., Sippl, W., Hoener, M. C., Arenas, E., & Liang, S. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00600-z · Cited by 60
Zhong, Q., & Zhu, F. (2022) · Neuroepidemiology · doi:10.1159/000524208 · Cited by 57
Wireless Deep Brain Stimulation by Ultrasound-Responsive Molecular Piezoelectric Nanogenerators
Chen, P., Cheng, C., Yang, X., Sha, T., Zou, X., Zhang, F., Jiang, W., Xu, Y., Cao, X., You, Y., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c10227 · Cited by 57
Liao, J., He, W., Li, L., Wang, J., Gong, L., Zhang, Q., & Lin, Z. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100016 · Cited by 63
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · Cells · doi:10.3390/cells14151161 · Cited by 58
Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson's models
He, H., Xiong, X., Zhou, S., Zhang, X., Zhao, X., Chen, L., & Xie, C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105297 · Cited by 56
Sekiya, H., Tsuji, A., Hashimoto, Y., Takata, M., Koga, S., Nishida, K., Futamura, N., Kawamoto, M., Kohara, N., Dickson, D. W., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01440-6 · Cited by 58
Care access and utilization among medicare beneficiaries living with Parkinson’s disease
Pearson, C. F., Hartzman, A., Munevar, D., Feeney, M. P., Dolhun, R., Todaro, V., Rosenfeld, S., Willis, A. W., & Beck, J. C. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00523-y · Cited by 65
Zhao, S., Dai, G., Li, J., Zhu, X., Huang, X., Li, Y., Tan, M., Wang, L., Fang, P., Chen, X., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-023-00983-9 · Cited by 67
Yang, S., & Zhu, G. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210915122820 · Cited by 58
Parkinson’s disease as a somato-cognitive action network disorder
Ren, J., Zhang, W., Dahmani, L., Gordon, E. M., Li, S., Zhou, Y., Long, Y., Huang, J., Zhu, Y., Guo, N., et al. (2026) · Nature · doi:10.1038/s41586-025-10059-1 · Cited by 55
Yan, Y., Ren, S., Duan, Y., Lu, C., Niu, Y., Wang, Z., Inglis, B., Ji, W., Zheng, Y., & Si, W. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00242-3 · Cited by 51
Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
Cuenca‐Bermejo, L., Almela, P., Navarro‐Zaragoza, J., Fernández‐Villalba, E., Cuello, A. M. G., Laorden, M. L., & Herrero, M. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413488 · Cited by 53
Mitochondrial Sirtuins in Parkinson’s Disease
He, L., Wang, J., Yang, Y., Li, J., & Tu, H. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03560-w · Cited by 55
Therapeutic potential of Polygala saponins in neurological diseases
Zhang, L., Yong, Y.-Y., Deng, L., Wang, J., Law, B. Y. K., Hu, M.-L., Wu, J., Yu, L., Wong, V. K. W., Yu, C., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154483 · Cited by 53
Potential therapeutic use of plant flavonoids in AD and PD
Meng-zhen, S., Ju, L., Zhang, L., Cai-feng, D., Shu-da, Y., Hao-fei, Y., & Wei-yan, H. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11440 · Cited by 56
Guo, W., Ji, M., Li, Y., Qian, M., Qin, Y., Li, W., Nie, H., Lv, W., Jiang, G., Huang, R., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122622 · Cited by 56
Han, Z., Wang, B., Wen, Y., Li, Y.-N., Feng, C., Ding, X.-S., Shen, Y., Yang, Q., & Gao, L. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.07.018 · Cited by 53
Ma, Q., Tian, J.-L., Lou, Y., Guo, R., Ma, X.-R., Wu, J., Yang, J., Tang, B.-J., Li, S., Qiu, M. S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115266 · Cited by 60
Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease
Bonam, S. R., Tranchant, C., & Muller, S. (2021) · Cells · doi:10.3390/cells10123547 · Cited by 54
Parkinson's disease and oral health: A systematic review
Verhoeff, M. C., Eikenboom, D., Koutris, M., de Vries, R., Berendse, H. W., van Dijk, K. D., & Lobbezoo, F. (2023) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2023.105712 · Cited by 52
Engineered bacterial extracellular vesicles for central nervous system diseases
Ji, N., Wang, F., Wang, M., Zhang, W. C., Liu, H., & Su, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.027 · Cited by 52
Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy
Choi, I., Heaton, G. R., Lee, Y.-K., & Yue, Z. (2022) · Science Advances · doi:10.1126/sciadv.abn1298 · Cited by 54
Wu, K., Wang, X., Gong, L., Zhai, X., Wang, K., Qiu, X., Zhang, H., Tang, Z., Jiang, H., & Wang, X. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115521 · Cited by 51
Peri‐operative management of patients with Parkinson’s disease
Yim, R., Leung, K. M. M., Poon, C. C. M., & Irwin, M. G. (2022) · Anaesthesia · doi:10.1111/anae.15617 · Cited by 50
Neuroinflammation in Parkinson’s Disease: From Gene to Clinic: A Systematic Review
Castillo-Rangel, C., Marín, G., Hernández-Contreras, K. A., Vichi-Ramírez, M. M., Zarate-Calderon, C., Torres-Pineda, O., Díaz-Chiguer, D. L., González, D. D. L. M., Apo, E. G., Teco-Cortes, J. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065792 · Cited by 55
Magnetic Resonance Elastography in the Study of Neurodegenerative Diseases
Feng, Y., Murphy, M. C., Hojo, E., Li, F. Y., & Roberts, N. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28747 · Cited by 52
CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease
Pinjala, P., Tryphena, K. P., Prasad, R., Khatri, D. K., Sun, W., Singh, S. B., Gugulothu, D. B., Srivastava, S., & Vora, L. K. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00381-y · Cited by 57
Emerging strategies, applications and challenges of targeting NAD+ in the clinic
Zhang, J., Wang, H., Lautrup, S., Nilsen, H. L., Treebak, J. T., Watne, L. O., Selbæk, G., Wu, L. E., Omland, T., Pirinen, E., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00947-6 · Cited by 63
Dong, H., Zhang, X., Duan, Y., He, Y., Zhao, J., Wang, Z., Wang, J., Li, Q., Fan, G., Liu, Z., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03070-2 · Cited by 49
Photoinduced elimination of senescent microglia cells in vivo by chiral gold nanoparticles
Xu, Z., Qu, A., Zhang, H., Wang, W., Hao, C., Lu, M., Shi, B., Xu, L., Sun, M., Xu, C., et al. (2022) · Chemical Science · doi:10.1039/d2sc01662a · Cited by 49
Anti-Inflammatory Effects of Flavonoids in Common Neurological Disorders Associated with Aging
Martínez‐Coria, H., Arrieta‐Cruz, I., Juárez, R. G., & López-Valdés, H. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054297 · Cited by 51
Fuzzy Drug Targets: Disordered Proteins in the Drug-Discovery Realm
Saurabh, S., Nadendla, K., Purohit, S. S., Sivakumar, P. M., & Çetinel, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c07708 · Cited by 51
Neurological Insights into Sleep Disorders in Parkinson’s Disease
Thangaleela, S., Sivamaruthi, B. S., Kesika, P., Mariappan, S., Rashmi, S., Choeisoongnern, T., Sittiprapaporn, P., & Chaiyasut, C. (2023) · Brain Sciences · doi:10.3390/brainsci13081202 · Cited by 55
Role of Brain Liver X Receptor in Parkinson’s Disease: Hidden Treasure and Emerging Opportunities
Alnaaim, S. A., Al-Kuraishy, H. M., Alexiou, A. T., Papadakis, M., Saad, H. M., & Batiha, G. E. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03561-y · Cited by 52
Lin, H. R., Li, D., Zhu, J., Liu, S., Li, J., Yu, T., Tuchin, V. V., SEMYACHKINA-GLUSHKOVSKAYA, O. V., & Zhu, D. Y. (2024) · Neurophotonics · doi:10.1117/1.nph.11.1.010601 · Cited by 60
Kuntić, M., Hahad, O., Münzel, T. F., & Daiber, A. (2024) · Antioxidants · doi:10.3390/antiox13030266 · Cited by 53
Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease
Flores-Ponce, X., & Velasco, I. (2024) · Metabolomics · doi:10.1007/s11306-024-02181-4 · Cited by 59
Boice, J. D., Quinn, B. M., Al‐Nabulsi, I., Ansari, A. J., Blake, P. K., Blattnig, S. R., Caffrey, E., Cohen, S. S., Golden, A. P., Held, K. D., et al. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1988183 · Cited by 49
Functional Brain Dysconnectivity in Parkinson's Disease: A 5‐Year Longitudinal Study
Yassine, S., Gschwandtner, U., Auffret, M., Achard, S., Vérin, M., Fuhr, P., & Hassan, M. (2022) · Movement Disorders · doi:10.1002/mds.29026 · Cited by 49
The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders
Terrabuio, E., Zenaro, E., & Constantin, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1233870 · Cited by 51
Camacho, M., Wilms, M., Almgren, H., Amador, K., Camicioli, R. M., Ismail, Z., Monchi, O., Forkert, N. D., & Initiative, A. D. N. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00647-9 · Cited by 53
Kong, W., Li, X., Guo, X., Sun, Y., Chai, W., Chang, Y., Huang, Q., Wang, P., & Wang, X. (2024) · ACS Nano · doi:10.1021/acsnano.3c05864 · Cited by 50
Autophagy‐associated non‐coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis
Hussain, M. S., Moglad, E. H. O., Afzal, M., Sharma, S., Gupta, G., Sivaprasad, G. V., Deorari, M., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14763 · Cited by 48
Su, C., Hou, Y., Xu, J., Xu, Z., Zhou, M., Ke, A., Li, H., Xu, J., Brendel, M., Maasch, J. R. M. A., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01175-9 · Cited by 56
Self-citationPamphlett, R., & Bishop, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262464 · Cited by 48
Role of platelet in Parkinson’s disease: Insights into pathophysiology & theranostic solutions
Beura, S. K., Panigrahi, A. R., Yadav, P., & Singh, S. K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101681 · Cited by 47
Tortorella, I., Argentati, C., Emiliani, C., Morena, F., & Martino, S. (2022) · Cells · doi:10.3390/cells11193093 · Cited by 47
Muscle Strength and Power in People With Parkinson Disease: A Systematic Review and Meta-analysis
Gamborg, M., Hvid, L. G., Thrue, C., Johansson, S., Franzén, E., Dalgas, U., & Langeskov‐Christensen, M. (2022) · Neurology Report · doi:10.1097/npt.0000000000000421 · Cited by 50
Müller-Nedebock, A. C., Dekker, M. C. J., Farrer, M. J., Hattori, N., Lim, S., Mellick, G. D., Rektorová, I., Salama, M., Schuh, A. F. S., Stoessl, A. J., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00535-8 · Cited by 49
Self-citationNeutrophil to lymphocyte ratio in parkinson’s disease: a systematic review and meta-analysis
Hosseini, S., Shafiabadi, N., Khanzadeh, M., Ghaedi, A., Ghorbanzadeh, R., Azarhomayoun, A., Bazrgar, A., Pezeshki, J., Bazrafshan, H., & Khanzadeh, S. (2023) · BMC Neurology · doi:10.1186/s12883-023-03380-7 · Cited by 49
Jain, A., Madkan, S., & Patil, P. (2023) · Cureus · doi:10.7759/cureus.47861 · Cited by 50
Friend or foe: Lactate in neurodegenerative diseases
Wang, M., Zhou, Y., Li, W., Zhu, L., & Liu, D. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102452 · Cited by 48
The epigenetic modification of DNA methylation in neurological diseases
Li, L., Chen, R., Zhang, H., Li, J., Huang, H., Weng, J., Tan, H., Guo, T., Wang, M., & Xie, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401962 · Cited by 54
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
